ClinicalTrials.gg
RecruitingNCT05851768Updated Jun 30, 2026

Efficacy of Dexmedetomidine VS Magnesium Sulphate With Bupivacaine in Erector Spinae Block for Thoracotomy Pain

An interventional study of Bupivacaine and Bupivacaine + Magnesium in Analgesia, sponsored by National Cancer Institute, Egypt. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by National Cancer Institute, Egypt · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Postoperative pain management is considered an integral part of perioperative care in patients undergoing thoracotomy. In order to reduce these complications, multiple regional techniques have been developed for thoracotomy including Intercostal nerve block, Erectospinae plane block and serratus block. Multiple adjuvants have been used in regional analgesia including adrenaline,clonidine,magnesium sulphate,dexmedatomidine and opoids.

02

Conditions studied

  • Analgesia
03

In context

Lead sponsor

National Cancer Institute, Egypt is the lead sponsor of 133 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from 18 to 65 years.
  • Male and female sexes.
  • .,III
  • Cancer patients undergoing thoracotomy incisions
  • (BMI) from 18.5 to 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Patient refusal
  • Known allergy to any of the used drugs
  • Low count, any coagulation defect
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Erector spinae plane block with 0.25% bupivacaine

    Patients will receive ultrasound guided ESPB with 0.25% bupivacaine

    Drug: Bupivacaine

  • Experimental
    Erector spinae plane block with 0.25% bupivacaine and Magnesium

    Patients will receive ultrasound guided ESPB with 0.25% bupivacaine and magnesium

    Drug: Bupivacaine + Magnesium

  • Experimental
    Erector spinae plane block with 0.25% bupivacaine and Dexmedetomidine

    Patients will receive ultrasound guided ESPB with 0.25% bupivacaine and dexmedetomidine

    Drug: Bupivacaine + Dexmedetomidine

Interventions

06

What researchers measure

Primary outcomes

  1. Total postoperative morphine consumption

    Total dose of morphine needed postoperatively in the first 24 h

    Time frame: First 24 hours postoperatively

Secondary outcomes

  1. Time to first postoperative rescue analgesia.

    Time to first postoperative rescue analgesia.

    Time frame: First 24 hours postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Information is available upon reasonable request through contacting the corresponding investigator

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Nov 2026, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2023
First posted
May 10, 2023
StartActual
May 15, 2023
Primary completionEst.
Nov 25, 2026
CompletionEst.
Dec 27, 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05851768
Responsible party
Walaa Youssef Elsabeeny (Assistant professor of Anesthesia and Pain management, National Cancer Institute, Egypt) — Principal investigator
First posted
May 10, 2023
Start date
May 15, 2023
Primary completion
Nov 25, 2026 (estimated)
Completion
Dec 27, 2026 (estimated)
Last update
Jun 30, 2026

Study contacts

Walaa Y Elsabeeny, MD
Contact
walaa.elsabeeny@nci.cu.edu.eg
01007798466 ext. +2
Ahmed A Mohamed, MD
Contact
ahmed.aboali7268@gmail.com
01272222923 ext. +2
Walaa Y Elsabeeny, MD
principal investigator · Assistant professor of Anesthesia and Pain Management, National Cancer Institute, Cairo University
Ahmed A Mohamed, MD
study director · Professor of Anesthesia,Surgical intensive care and Pain management,Faculty of medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Magnesium · Dexmedetomidine

Start the discussion